SCHEMBL4833441

SCHEMBL4833441

CON(C)C(=O)C(O[Si](C)(C)C(C)(C)C)c1ccc(F)cc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.37
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
CYP26A1 O43174 1/20 0.34
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
HPGD P15428 1/20 0.32
AOC3 Q16853 1/20 0.32
TSHR P16473 1/20 0.32
TXNRD1 Q16881 1/20 0.32
NPC1 O15118 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7725831 0.88 FAAH (0.38) FAAHCYP26A1HPGDALDH1A1
SCHEMBL4839775 0.87 TEAD1 (0.37) FAAHCYP26A1
SCHEMBL4833715 0.86 ATM (0.36) FAAHAOC3ALDH1A1KMT2A
SCHEMBL18568034 0.75 KDM4E (0.32) FAAHADRB2ADRB1ADRB3ALDH1A1
SCHEMBL15049932 0.74 ADRB2 (0.38) ADRB2ADRB1ADRB3AOC3TSHR
SCHEMBL15049933 0.74 ADRB2 (0.38) ADRB2ADRB1ADRB3AOC3TSHR
SCHEMBL29529432 0.74 ADRB2 (0.38) ADRB2ADRB1ADRB3AOC3TSHR
SCHEMBL13786048 0.74 AOC3 (0.37) AOC3
SCHEMBL7355965 0.74 LTA4H (0.43) CYP26A1ADRB2ADRB1ADRB3NPC1
SCHEMBL4838298 0.72 FAAH (0.45) FAAHDPP4DPP8HPGDAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320995-B2 Benzimidazoles and benzothiazoles as inhibitors of map kinase ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1554272-B1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE LILLY CO ELI (US) 2006-10-25 EP disclosed
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase EIL LILLY AND COMPANY (US) 2005-12-08 US disclosed
EP-1554272-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2005-07-20 EP disclosed
WO-2004014900-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase MAP3K8, MAPK8, MAPK1 FAAH 4425/4885DPP4 2141/4885DPP8 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.